Back to Search
Start Over
Thrombus aspiration and prehospital ticagrelor administration in ST-elevation myocardial infarction: Findings from the ATLANTIC trial.
- Source :
-
American heart journal [Am Heart J] 2018 Feb; Vol. 196, pp. 1-8. Date of Electronic Publication: 2017 Oct 03. - Publication Year :
- 2018
-
Abstract
- Background: The potential interactions between prehospital (pre-H) ticagrelor administration and thrombus aspiration (TA) in patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) have never been studied. Therefore, we evaluated the potential benefit of TA and pre-H ticagrelor treatment in patients enrolled in the ATLANTIC trial (NCT01347580).<br />Methods: This analysis included 1,630 patients who underwent primary PCI. Multivariate analysis was used to explore the potential association of TA and pre-H treatment to clinical outcomes. Potential interactions between TA and pre-H ticagrelor were also explored.<br />Results: A total of 941 (57.7%) patients underwent TA. In adjusted multivariate logistic model, pre-H ticagrelor treatment was significantly associated with less frequent new MI or definite stent *thrombosis (ST) (odds ratio [OR] 0.43, 95% CI 0.20-0.92, P=.031), or definite ST (OR 0.26, 95% CI 0.07-0.91, P=.036) at 30 days. Patients treated with TA had higher frequency of Thrombolysis in Myocardial Infarction (TIMI) flow 0-1 compared with no-TA group (80.7% vs 51.9%, P<.0001). TA when also adjusted for TIMI flow 0-1 showed significant association only for higher bailout use of glycoprotein IIb/IIIa inhibitors (OR 1.72, 95% CI 1.18-2.50, P=.004) and more frequent 30-day TIMI major bleeding (OR 2.92, 95% CI 1.10-7.76, P=.032). No significant interactions between TA and pre-H ticagrelor were present for the explored end points.<br />Conclusions: TA when left to physicians' discretion was used in high-risk patients, was associated with bailout use of glycoprotein IIb/IIIa inhibitors and TIMI major bleeding, and had no impact on 30-day clinical outcomes. Conversely, pre-H ticagrelor treatment predicted lower 30-day rates of ST or new MI without interaction with TA.<br /> (Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Age Factors
Aged
Combined Modality Therapy
Coronary Angiography methods
Double-Blind Method
Female
Humans
Internationality
Male
Middle Aged
Multivariate Analysis
Predictive Value of Tests
Prognosis
Risk Assessment
ST Elevation Myocardial Infarction mortality
Sex Factors
Survival Rate
Treatment Outcome
Emergency Medical Services methods
Percutaneous Coronary Intervention methods
ST Elevation Myocardial Infarction diagnostic imaging
ST Elevation Myocardial Infarction therapy
Ticagrelor therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6744
- Volume :
- 196
- Database :
- MEDLINE
- Journal :
- American heart journal
- Publication Type :
- Academic Journal
- Accession number :
- 29421001
- Full Text :
- https://doi.org/10.1016/j.ahj.2017.09.018